

SWISS EXPERIENCE AND LATEST UPDATES IN CKD



CHAIRMAN

PROF. EM. MICHEL BURNIER,
University of Lausanne

Epidemiology and burden of CKD-associated pruritus: Recent data from Switzerland



PROF. NANCY HELOU
HESAV LAUSANNE



PROF. PATRICE AMBÜHL
STADTSPITAL ZÜRICH

Strengthen cardiorenal protection in T2D-patients and CKD – recent data and real life experience with nsMRA




DR. ANTONIO BELLASI
EOC LUGANO

CSL Vifor



SGN-SSN
Schweizerische Gesellschaft für Nephrologie
Società Svizzera di Nefrologia
Società Svizzera di Nefrologia
Swiss Society of Nephrology



SGN WILL
PROVIDE
1 CREDIT
POINT FOR
ATTENDING



Tuesday, 5 November
6:00 – 7:30 pm

- 18:00 INTRODUCTION BY CHAIRMAN
- 18:10 **EPIDEMIOLOGY AND BURDEN OF CKD-ASSOCIATED PRURITUS: RECENT DATA FROM SWITZERLAND**
- 18:40 QUESTIONS & ANSWERS
- 18:50 **STRENGTHEN CARDIORENAL PROTECTION IN T2D-PATIENTS AND CKD – RECENT DATA AND REAL LIFE EXPERIENCE WITH NSMRA**
- 19:20 QUESTIONS & ANSWERS
- 19:30 CONCLUSIONS / TAKE-HOME MESSAGES

Kerendia® - Film-coated tablets with 10 mg and 20 mg finerenone, List B. Bayer (Schweiz) AG, 8045 Zürich.
Please refer to the Swiss SmPC under www.swissmedicinfo.ch

Kapruvia® - vials containing 1 ml/50 µg Difelikefalin, injectable solution, List B. Vifor Fresenius Medical Care Renal Pharma Ltd, CH-9001 St. Gallen. Please refer to the Swiss SmPC under www.swissmedicinfo.ch

CKD = chronic kidney disease, T2D = Type 2 diabetes, nsMRA= non-steroidal mineralocorticoid receptor antagonist

FREE REGISTRATION



PP-KER-CH-0158-1 09/2024
CH-DFK-2400051